

CLAIMS

[Claim 1]. Use of an antibody against calnexin (Cnx) in the manufacture of a medicament for the treatment of cancer, wherein the antibody inhibits Cnx and antibody-mediated inhibition of Cnx reduces or inhibits tumor growth.

5 [Claim 2]. An antibody against Cnx for use according to Claim 1, wherein the method of treatment or prevention of cancer reduces or inhibits extracellular matrix (ECM) degradation.

[Claim 3]. An antibody against Cnx for use according to Claim 1, wherein the treatment or prevention of cancer involves the prevention of ECM degradation by cancer cells.

10 [Claim 4]. The use according to claim 1, wherein the antibody against Cnx is capable of inhibiting:

- (a) an ECM degradation activity of the Cnx/ERp57 complex; or
- (b) an oxidoreductase activity of the Cnx/ERp57 complex; or
- (c) a disulphide bond reductase activity of the Cnx/ERp57 complex.

15 [Claim 5]. The use according to any one of claims 1 to 4, in which the cancer comprises invasive or metastatic cancer.

[Claim 6]. The use according to claim 5, wherein the medicament is for the treatment or prevention of metastasis.

[Claim 7]. The use according to any one of claims 1 to 6, in which the cancer is characterised by elevated levels of O-glycosylation.

20 [Claim 8]. The use according to claim 7, wherein the cancer is characterised by elevated levels of endoplasmic reticulum (ER) O-glycosylation, or elevated levels of O-glycosylation of Cnx.

25 [Claim 9]. The use according to claim 7 or 8, wherein the cancer is selected from the group consisting of: liver, breast, sarcoma, lung, prostate, bladder, kidney, melanoma, pancreatic, endometrial, colorectal and thyroid cancer.

[Claim 10]. The use according to any previous claim, wherein the cancer is characterised by increased Cnx expression.

[Claim 11]. An antibody against Cnx for use according to any one of the previous claims, wherein the cancer is characterised by cell surface exposure of the Cnx/ERp57 complex.

[Claim 12]. The use according to any previous claim, wherein the antibody is monoclonal.

5 [Claim 13]. The use according to any previous claim, wherein the antibody is humanised.

[Claim 14]. The use according to any preceding claim, in which the antibody against Cnx is an Fv, F(ab') and F(ab')₂, or scFv antibody.

10 [Claim 15]. An antibody against Cnx for use according to any one of claims 2 to 14, wherein inhibition of ECM degradation is determined through an ECM degradation assay.